Mesenchymal stromal cells for acute graft‐versus‐host disease: response at 1 week predicts probability of survival

Mesenchymal stromal cells (MSCs) have been successfully used for the treatment of steroid‐resistant graft‐versus‐host‐disease (GvHD). However, the lack of early predictors of clinical responses impacts on the time at which to add further treatment and consequently the design of informative clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Galleu, Antonio, Milojkovic, Dragana, Deplano, Simona, Szydlo, Richard, Loaiza, Sandra, Wynn, Robert, Marks, David I., Richardson, Deborah, Orchard, Kim, Kanfer, Edward, Tholouli, Eleni, Saif, Muhammad, Sivaprakasam, Ponni, Lawson, Sarah, Bloor, Adrian, Pagliuca, Antonio, Potter, Victoria, Mehra, Varun, Snowden, John A., Vora, Ajay, Kishore, Bhuvan, Hunter, Hannah, Apperley, Jane F., Dazzi, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Haematological Malignancy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6916615/
https://www.ncbi.nlm.nih.gov/pubmed/30637732
http://dx.doi.org/10.1111/bjh.15749

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6916615/
https://www.ncbi.nlm.nih.gov/pubmed/30637732
http://dx.doi.org/10.1111/bjh.15749

Ejemplares similares